While oncology dominates the commercialized cell regeneration medicine market, cardiovascular applications represent a frontier of transformative potential that addresses the leading global cause of mortality and morbidity. Heart failure, affecting over 64 million people worldwide, remains inadequately treated by pharmacological and device interventions that manage symptoms but fail to restore...